To PhillipCapital’s Paul Chew, Hyphens Pharma’s results met expectations, with revenue and patmi reaching 55% and 46% of his forecasts respectively.
Analysts at PhillipCapital and SAC Capital have kept their “buy” calls on pharmaceutical company, Hyphens Pharma, at unchanged target prices of 35 cents and 38 cents respectively.
For the 1HFY2024 ended June 30, Hyphens Pharma’s revenue came in 33.4% y-o-y higher to $99.6 million, while profit after tax and minority interests (patmi) grew 52% y-o-y to $5.4 million.
